Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Heat Biologics Inc (HTBX)

Heat Biologics Inc (HTBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 188,542
  • Shares Outstanding, K 25,410
  • Annual Sales, $ 2,950 K
  • Annual Income, $ -26,050 K
  • 60-Month Beta 0.34
  • Price/Sales 63.18
  • Price/Cash Flow N/A
  • Price/Book 1.45
Trade HTBX with:

Options Overview

Details
  • Implied Volatility 128.64%
  • Historical Volatility 54.05%
  • IV Percentile 58%
  • IV Rank 20.60%
  • IV High 171.78% on 03/08/21
  • IV Low 117.44% on 04/07/21
  • Put/Call Vol Ratio 0.13
  • Today's Volume 488
  • Volume Avg (30-Day) 474
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 9,641
  • Open Int (30-Day) 8,356

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +129,840.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.84 +8.48%
on 03/30/21
9.28 -20.04%
on 03/12/21
-1.02 (-12.09%)
since 03/09/21
3-Month
5.82 +27.49%
on 01/11/21
17.00 -56.35%
on 02/09/21
+1.44 (+24.08%)
since 01/08/21
52-Week
3.50 +112.00%
on 04/24/20
30.10 -75.35%
on 07/21/20
+3.64 (+96.30%)
since 04/09/20

Most Recent Stories

More News
Heat Biologics Provides Year-End Business Update

Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates...

HTBX : 7.42 (+1.23%)
Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including...

HTBX : 7.42 (+1.23%)
Thinking about buying stock in Ovid Therapeutics, KemPharm, Super League Gaming, Heat Biologics, or TherapeuticsMD?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OVID, KMPH, SLGG, HTBX, and TXMD.

KMPH : 9.15 (-10.21%)
OVID : 3.69 (unch)
SLGG : 6.38 (-6.59%)
TXMD : 1.3200 (unch)
HTBX : 7.42 (+1.23%)
Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...

HTBX : 7.42 (+1.23%)
Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027

, /PRNewswire/ -- The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians are looking for alternate therapies,...

BIOV.CN : 0.440 (+4.76%)
LMNGF : 0.3500 (+4.29%)
KALV : 26.15 (+0.08%)
HTBX : 7.42 (+1.23%)
BMS : 57.25 (-1.43%)
TYME : 1.6500 (-2.94%)
ONTX : 0.8216 (-2.84%)
Thinking about buying stock in Heat Biologics, Zosano Pharma, Glu Mobile, AzurRx BioPharma, or Abeona Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTBX, ZSAN, GLUU, AZRX, and ABEO.

GLUU : 12.47 (+0.08%)
ABEO : 1.6400 (-1.80%)
AZRX : 0.9300 (-2.72%)
HTBX : 7.42 (+1.23%)
ZSAN : 1.2100 (-0.82%)
Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab

HTBX : 7.42 (+1.23%)
Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Spike specific CD8+ and CD4+ T-cell memory responses observed 30- and 60- days post vaccination

HTBX : 7.42 (+1.23%)
Thinking about buying stock in Phio Pharmaceuticals, Allena Pharmaceuticals, Aemetis, Atossa Therapeutics, or Heat Biologics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHIO, ALNA, AMTX, ATOS, and HTBX.

ALNA : 1.3000 (-2.99%)
AMTX : 26.10 (-0.34%)
PHIO : 2.74 (-1.08%)
ATOS : 2.02 (-1.94%)
HTBX : 7.42 (+1.23%)
Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...

HTBX : 7.42 (+1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company's products under development include HS-110 for the treatment of non-small cell...

See More

Key Turning Points

3rd Resistance Point 7.89
2nd Resistance Point 7.72
1st Resistance Point 7.57
Last Price 7.42
1st Support Level 7.25
2nd Support Level 7.08
3rd Support Level 6.93

See More

52-Week High 30.10
Fibonacci 61.8% 19.94
Fibonacci 50% 16.80
Fibonacci 38.2% 13.66
Last Price 7.42
52-Week Low 3.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar